Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Trujillo

Showing results (51-60 of 57) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 57 results.
ACS Medicinal Chemistry Letters|January 19, 2019
Aminopyrazole Carboxamide Bruton's Tyrosine Kinase Inhibitors. Irreversible to Reversible Covalent Reactive Group TuningMark E Schnute, Stephen E Benoit, Ingrid P Buchler, et al.
Journal of Medicinal Chemistry|August 17, 2018
Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)Andrew Fensome, Catherine M Ambler, Eric Arnold, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of an Oral Potent Selective Inhibitor of Hematopoietic Prostaglandin D Synthase (HPGDS)Chris P Carron, John I Trujillo, Kirk L Olson, et al.
Nature Communications|March 10, 2026
Discovery of an ITK and TRK kinase inhibitor for the potential topical treatment of atopic dermatitisJennifer L Duffen, Kimberly K Crouse, Lin Ji, et al.
Journal of Medicinal Chemistry|September 22, 2025
Discovery of PF-07054894, a Potent Squaramide-Based CCR6 Antagonist Displaying High CXCR2 SelectivityMark E Schnute, Huixian Wu, John I Trujillo, et al.
ACS Medicinal Chemistry Letters|August 20, 2025
Peptidylarginine Deiminase (PAD) Inhibitor Optimization through Displacement of a Trapped Water MoleculeMark E Schnute, Gary M Chinigo, Kentaro Futatsugi, et al.
Journal of Medicinal Chemistry|August 22, 2018
Discovery of 3-Cyano- N-(3-(1-isobutyrylpiperidin-4-yl)-1-methyl-4-(trifluoromethyl)-1 H-pyrrolo[2,3- b]pyridin-5-yl)benzamide: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor C2 Inverse AgonistMark E Schnute, Mattias Wennerstål, Jennifer Alley, et al.
Pageof 6

Showing results (51-60 of 57) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 57 results.
ACS Medicinal Chemistry Letters|January 19, 2019
Aminopyrazole Carboxamide Bruton's Tyrosine Kinase Inhibitors. Irreversible to Reversible Covalent Reactive Group TuningMark E Schnute, Stephen E Benoit, Ingrid P Buchler, et al.
Journal of Medicinal Chemistry|August 17, 2018
Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)Andrew Fensome, Catherine M Ambler, Eric Arnold, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of an Oral Potent Selective Inhibitor of Hematopoietic Prostaglandin D Synthase (HPGDS)Chris P Carron, John I Trujillo, Kirk L Olson, et al.
Nature Communications|March 10, 2026
Discovery of an ITK and TRK kinase inhibitor for the potential topical treatment of atopic dermatitisJennifer L Duffen, Kimberly K Crouse, Lin Ji, et al.
Journal of Medicinal Chemistry|September 22, 2025
Discovery of PF-07054894, a Potent Squaramide-Based CCR6 Antagonist Displaying High CXCR2 SelectivityMark E Schnute, Huixian Wu, John I Trujillo, et al.
ACS Medicinal Chemistry Letters|August 20, 2025
Peptidylarginine Deiminase (PAD) Inhibitor Optimization through Displacement of a Trapped Water MoleculeMark E Schnute, Gary M Chinigo, Kentaro Futatsugi, et al.
Journal of Medicinal Chemistry|August 22, 2018
Discovery of 3-Cyano- N-(3-(1-isobutyrylpiperidin-4-yl)-1-methyl-4-(trifluoromethyl)-1 H-pyrrolo[2,3- b]pyridin-5-yl)benzamide: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor C2 Inverse AgonistMark E Schnute, Mattias Wennerstål, Jennifer Alley, et al.
Pageof 6